OurCongressPublic Data • Non-Partisan
Built to help voters quickly verify how officials vote — district first, party second. All information is sourced from official public records.
← Back to bills
HR. 1672 · 119th Congress

Maintaining Investments in New Innovation Act

In committee

This bill has not become law. Status shown reflects the latest official action.

See what this could mean for your district

Save your district in Account to view district-specific context for this bill.

Set my district

Bill details

Introduced: 2/27/2025
Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill ID: 119hr1672
Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary

Introduced in House

Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Source: BILLSUM · Summary date: 2/27/2025

District impact notes

1 notes
NEUTRAL
3/29/2026

The Maintaining Investments in New Innovation Act sets a requirement for drug products using genetically targeted technology to have market approval for at least 11 years to qualify for Medicare price negotiations. • This policy could affect local healthcare providers and patients by potentially influencing the availability and pricing of certain prescription drugs. • Local institutions involved in healthcare may need to adjust their strategies based on how drug pricing negotiations evolve under this program. • There may be questions about how this timeline could impact the introduction of new treatments and the balance between innovation and cost control in the healthcare system. AI-generated from official bill summary and plain-English note; verify with official text.

Related votes

Roll calls that reference this bill in official data.

0 roll calls
No related roll calls found yet for this bill.

Primary sources

Official links to verify details. (No interpretation.)

Summary source label: BILLSUM
Congress.gov bill →GovInfo bill text (BILLS) →GovInfo summaries (BILLSUM) →OurCongress methodology →
About this data
  • OurCongress is non-partisan by design. We do not add political interpretation or advocacy.
  • Bill data and official summaries come from GovInfo and Congress.gov. Some bills do not have published summaries yet.
  • District impact notes (when shown) are AI-generated from official bill metadata/summaries to improve readability. They are not official government language.
  • This page updates automatically via a daily ingestion pipeline.

About this data

Non-partisan by design
OurCongress provides plain-English context without endorsements, political interpretation, or advocacy.
Official sources
Data is sourced from official government records (e.g., Congress.gov, GovInfo, Clerk of the House, and the U.S. Senate).
AI-generated text
Some sections may be AI-generated from official summaries/metadata to help readability. AI output can be imperfect—verify with primary sources.
Last updated: 3/29/2026Source: BILLSUMBill: 119hr1672Learn more →